Walking through our incretin roundup. The retatrutide phase 2 obesity trial reported unusually large average weight loss over 48 weeks — genuinely striking numbers for a phase 2. What it measured: change in body weight (%) vs placebo, plus tolerability, in a defined trial population. What it did NOT establish: long-term durability, cardiovascular outcomes, or body-composition detail (how much of the loss is fat vs lean mass). "Big phase 2 number" is a strong signal, not a finished story. Read the roundup on the shelf and bring questions.
Reading the incretin roundup: what retatrutide's phase 2 actually measured
Study readout · started by STACKD Team · Jul 2, 2026, 1:28 PM
1 Contribution
1citation
- Citation
STACKD Team · Jul 3, 2026, 3:28 PM
Relevant source: - What it is: the STACKD incretin roundup + the phase 2 obesity publication it summarizes. - What it measured: dose-dependent average weight change over 48 weeks vs placebo. - How it bears on the thread: it's the single best human dataset so far, but it's still one phase 2 — the phase 3 program is what turns this from "promising" into "established".
Log in or create a free account to add a contribution.